MedTrace Logo

Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease

NCT00857233 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 297

Last updated 2012-08-29

Study results available
· View outcomes & findings →

Summary

The primary objective of the study was to examine the safety and tolerability of memantine in outpatients with moderate to severe Alzheimer's Disease.

Conditions

Interventions

DRUG

Memantine

20 mg oral tablets once daily

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Primary Completion
2010-07-31
Completion
2010-10-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00857233 on ClinicalTrials.gov